(UPDATE: His replacement is Christian Cuzick, Cuzick announced after Dickinson said he was stepping down.)
J&J MedTech has reportedly been exploring a sale of its neurovascular business, which was previously known as Cerenovus. J&J this week named Michael Bodner as the new group chair of Electrophysiology and Neurovascular.
Medtech pay analysis: Johnson & Johnson discloses executive pay and new security measures
“From my first days in Ethicon in the U.K. to helping build our amazing Electrophysiology business and finally leading the Neurovascular team for the past six years as worldwide president,” Dickinson said in a post on LinkedIn today, “each year brought me incredible opportunities to learn, grow and work with brilliant people. I’m immensely proud of all we accomplished together.”
Dickinson said he is moving back to the U.K. “to be closer to family and explore new opportunities” after a decade in California.
“As I reflect on my time with Johnson & Johnson, it is clear to me that the people I had the privilege of working with not only shaped my journey but also profoundly influenced my growth as a leader,” Dickinson said. “I learned from each of you — your dedication, creativity, and resilience inspired me daily. At the same time, I took great pride in providing opportunities for others, nurturing talent and building a culture in my teams where everyone was welcomed, accepted and could thrive. Watching people grow, succeed, and achieve their goals has been one of the most rewarding aspects of my career. We are nothing without great people around us.”
“Thank you for the memories and the friendships, I will cherish them,” he continued. “Here’s to the future!”
Related: Mark Dickinson on the future of stroke care
This post was originally published on March 14, 2025, and updated on March 17 with news of Dickinson’s replacement.
